Claus Garbe
Impact in
- Oncology top 0.01%
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Dermatology top 0.02%
- Skin Protection and Aging
- Cutaneous lymphoproliferative disorders research
Papers in
- Oncology 469
- Cutaneous Melanoma Detection and Management 340
- CAR-T cell therapy research 79
- Cancer Immunotherapy and Biomarkers 58
-
- Melanoma and MAPK Pathways 172
- Co-authors
- Ulrike Leiter (104 shared papers)Thomas Eigentler (157 shared papers)Axel Hauschild (105 shared papers)Birgit Schittek (53 shared papers)Friedegund Meier (73 shared papers)G. Rassner (50 shared papers)Dirk Schadendorf (96 shared papers)Jürgen Bauer (55 shared papers)
- Journals
- Journal of Clinical Oncology (84 papers)JDDG Journal der Deutschen Dermatologischen Gesellschaft (50 papers)Melanoma Research (39 papers)European Journal of Cancer (38 papers)British Journal of Dermatology (33 papers)
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Claus Garbe
736 papers receiving 34.2k citations
Claus Garbe's Hit Papers
Peers
Comparison fields: 5 of 182
- Oncology 18.4k
- Dermatology 4.5k
- Immunology 5.8k
- Molecular Biology 12.9k
- Immunology and Allergy 1.0k
Countries citing papers authored by Claus Garbe
This map shows the geographic impact of Claus Garbe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claus Garbe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claus Garbe more than expected).
Fields of papers citing papers by Claus Garbe
This network shows the impact of papers produced by Claus Garbe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claus Garbe. The network helps show where Claus Garbe may publish in the future.
Co-authors
The 25 scholars most cited alongside Claus Garbe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 754 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma Hit paper breakdown → | 2014 | 1506 |
| 2 | Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group Hit paper breakdown → | 2012 | 1071 |
| 3 | Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial Hit paper breakdown → | 2018 | 690 |
| 4 | Dermcidin: a novel human antibiotic peptide secreted by sweat glands Hit paper breakdown → | 2001 | 534 |
| 5 | Epidemiology of Melanoma and Nonmelanoma Skin Cancer—The Role of Sunlight Hit paper breakdown → | 2009 | 532 |
| 6 | Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma Hit paper breakdown → | 2017 | 482 |
| 7 | 2008 | 469 | |
| 8 | Melanoma Hit paper breakdown → | 2015 | 456 |
| 9 | Epidemiology of Skin Cancer Hit paper breakdown → | 2014 | 452 |
| 10 | 2011 | 431 | |
| 11 | Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma Hit paper breakdown → | 2009 | 417 |
| 12 | Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial Hit paper breakdown → | 2016 | 417 |
| 13 | Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2018 | 400 |
| 14 | 2003 | 394 | |
| 15 | Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline Hit paper breakdown → | 2015 | 377 |
| 16 | Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial Hit paper breakdown → | 2015 | 374 |
| 17 | 2016 | 350 | |
| 18 | Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline Hit paper breakdown → | 2015 | 344 |
| 19 | 2009 | 306 | |
| 20 | Epidemiology of Skin Cancer: Update 2019 Hit paper breakdown → | 2020 | 291 |
About Claus Garbe
Claus Garbe is a scholar working on Oncology, Molecular Biology, Immunology, Dermatology and Epidemiology, having authored 754 papers that have together received 34.9k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (340 papers), Melanoma and MAPK Pathways (172 papers), Immunotherapy and Immune Responses (95 papers), Nonmelanoma Skin Cancer Studies (81 papers), CAR-T cell therapy research (79 papers), Cancer Immunotherapy and Biomarkers (58 papers), Cutaneous lymphoproliferative disorders research (43 papers) and melanin and skin pigmentation (33 papers). The work is most often cited by research in Oncology (18.4k citations), Dermatology (4.5k citations), Immunology (5.8k citations), Molecular Biology (12.9k citations) and Immunology and Allergy (1.0k citations). Claus Garbe has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Ulrike Leiter, Thomas Eigentler, Axel Hauschild, Birgit Schittek, Friedegund Meier, G. Rassner, Dirk Schadendorf, Jürgen Bauer, Helmut Breuninger and Caroline Robert. Their work appears in journals such as Journal of Clinical Oncology, JDDG Journal der Deutschen Dermatologischen Gesellschaft, Melanoma Research, European Journal of Cancer and British Journal of Dermatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.